...
首页> 外文期刊>The American heart journal >Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial
【24h】

Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial

机译:左咪丹丹患者患有左心室收缩功能障碍的心肺手术旁路:左心室收缩功能障碍患者的左索亚丹丹的基本原理和研究设计需要心肺手术,需要心肺手术(Levo-CTS)试验

获取原文
获取原文并翻译 | 示例
           

摘要

Background Low cardiac output syndrome is associated with increased mortality and occurs in 3% to 14% of patients undergoing cardiac surgery on cardiopulmonary bypass (CPB). Levosimendan, a novel calcium sensitizer and K-ATP channel activator with inotropic, vasodilatory, and cardioprotective properties, has shown significant promise in reducing the incidence of low cardiac output syndrome and related adverse outcomes in patients undergoing cardiac surgery on CPB.
机译:背景技术较低的心脏输出综合征与增加的死亡率有关,并且发生在3%至14%的患者上进行心肺手术(CPB)。 Levosimendan,一种新型钙敏化剂和具有肌室,血管舒张和心脏保护性的K-ATP通道活化剂,对降低CPB心脏手术患者的低心输出综合征及相关不良结果的显着承诺。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号